Related Experiment Videos
[Transient liver damage due to prajmalium bitartrate]
Harefuah
|January 1, 1991
Summary
Three patients experienced transient cholestatic jaundice after taking prajmalium bitartrate, a Class I antiarrhythmic drug. This drug-induced liver injury resolved after discontinuing the medication.
Area of Science:
- Pharmacology
- Hepatology
- Toxicology
Background:
- Class I antiarrhythmic drugs are crucial for managing cardiac arrhythmias.
- Prajmalium bitartrate is utilized for its electrophysiological properties.
- Drug-induced liver injury (DILI) is a significant concern in clinical practice.
Observation:
- Three patients administered prajmalium bitartrate presented with transient cholestatic jaundice.
- Leukocyte inhibition tests indicated drug sensitivity (4%, 12%, 15% inhibition).
- Eosinophilia was observed in all affected patients.
Findings:
- The clinical presentation and laboratory findings suggest prajmalium bitartrate as the causative agent.
- Transient hepatic damage was strongly associated with drug exposure.
- Cessation of prajmalium bitartrate led to recovery of liver function.
Implications:
- This case series highlights the potential hepatotoxicity of prajmalium bitartrate.
- Physicians should consider DILI when patients on this antiarrhythmic develop jaundice.
- Further research into the mechanisms of prajmalium bitartrate-induced liver injury is warranted.